Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417789 · ClinicalTrials.gov registry record · Phase 3
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
A Phase 3 study of TGCT, sponsored by SynOx Therapeutics Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT05417789 is a Phase 3 study of TGCT that is active but no longer recruiting, run by SynOx Therapeutics Limited. The registered enrollment target is 128 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT05417789, a Phase 3 study of TGCT, is active but no longer recruiting, sponsored by SynOx Therapeutics Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. Part 2 is a long-term double-blind follow-up phase of the subjects on emactuzumab or placebo. Subjects assigned to placebo in Part 1 have the option, subject to eligibility, to crossover to receive open-label emactuzumab in Part 2. Subjects assigned to active drug in Part 1 have the option to receive open-label retreatment under certain circumstances.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emactuzumab
Study Locations (20)
California
- NextGen Oncology - Beverly Hills
- Sarcoma Oncology Research Center, LLC - Los Angeles
- USC Norris Comprehensive Cancer Center - Los Angeles
Other
- LKH-Universitätsklinikum Graz - Graz
- UZ Gent - Department of Medical Oncology - Ghent
Kansas
- University of Kansas Cancer Center (Overland Park) - USOR - Overland Park
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Duke Cancer Center - Durham
Ohio
- The Ohio State University - Columbus
Oregon
- OHSU Knight Cancer Institute Hematology Oncology - Portland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05417789
The ClinicalTrials.gov registry entry for NCT05417789 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SynOx Therapeutics Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with TGCT appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05417789 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Other, Kansas.
Frequently Asked Questions
What is clinical trial NCT05417789 about?
NCT05417789 is a clinical study titled "Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)". This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The...
What is the current status of trial NCT05417789?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2024-10-09. Estimated completion is 2027-09-30.
What conditions does trial NCT05417789 study?
This clinical trial studies the following conditions: TGCT.
What interventions are being tested in trial NCT05417789?
The interventions under investigation include: Placebo (DRUG), Emactuzumab (DRUG).
Who is sponsoring clinical trial NCT05417789?
This trial is sponsored by SynOx Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417789 being conducted?
This trial has 20 study locations across California, Kansas, Minnesota, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.